共 50 条
- [41] Efficacy of mucosal vaccination using a protozoan parasite as a vehicle for antigen delivery: IgG and neutralizing response after rectal administration of LeCoVax-2, a candidate vaccine against COVID-19PHARMACOLOGICAL RESEARCH, 2022, 186Epis, SaraVarotto-Boccazzi, IlariaManenti, AlessandroRubolini, DiegoGabrieli, PaoloCattaneo, Giulia MariaGourlay, LouiseDapporto, FrancescaMonti, MartinaRazzano, IlariaLeonardi, MargheritaIannacone, MatteoRecordati, CamillaBertola, LucaFiorina, PaoloMarvasi, LuigiMontomoli, EmanueleZuccotti, GianvincenzoBandi, Claudio
- [42] Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial (vol 181, pg 1612, 2021)JAMA INTERNAL MEDICINE, 2022, 182 (02) : 239 - 239Spyropoulos, Alex C.Goldin, MarkGiannis, DimitriosDiab, WassimWang, JaniceKhanijo, SameerMignatti, AndreaGianos, EugeniaCohen, MarcSharifova, GulruLund, Jeet M.Tafur, AlfonsoLewis, Paul A.Cohoon, Kevin P.Rahman, HusnearaSison, Cristina P.Lesser, Martin L.Ochani, KantaAgrawal, NiravHsia, JudithAnderson, Victoria E.Bonaca, MarcHalperin, Jonathan L.Weitz, Jeffrey I.
- [43] Safety and Efficacy of SARS-COV-2-Specific T Cells as Adoptive Immunotherapy for High-Risk COVID-19 Patients: A Phase I/II, Randomized Clinical TrialMOLECULAR THERAPY, 2022, 30 (04) : 551 - 551Papadopoulou, AnastasiaKaravalakis, GeorgePapadopoulou, EfthymiaXochelli, AlikiBousiou, ZoiVogiatzoglou, AnastasiosPapayanni, PenelopeGeorgakopoulou, AphroditeGiannaki, MariaStavridou, FaniVallianou, IoannaKammenou, MariaVarsamoudi, EvangeliaPapadimitriou, VasilikiGiannaki, ChrysavgiSileli, MariaStergiouda, ZoiStefanou, GaryfalliaKourlaba, GeorgiaTriantafyllidou, MariaSiotou, EleniKaraglani, AntoniaZotou, EleniChatzika, GeorgiaBoukla, AnnaApostolou, DimitraPitsiou, GeorgiaMorfesis, PetrosBartzoudis, DimitrisImprialos, KonstantinosKarampatakis, TheodorosKapravelos, NikolaosBitzani, MilitsaTheodorakopoulou, MariaSerasli, EvaSakellari, IoannaFylaktou, AsiminaTryfon, StavrosAnagnostopoulos, AchillesYannaki, Evangelia
- [44] SAFETY AND EFFICACY OF SARS-COV-2-SPECIFIC T CELLS AS ADOPTIVE IMMUNOTHERAPY FOR HIGH-RISK COVID-19 PATIENTS: A PHASE I/II, RANDOMIZED CLINICAL TRIALCYTOTHERAPY, 2022, 24 (05) : S37 - S38Papadopoulou, A.Karavalakis, G.Papadopoulou, E.Xochelli, A.Bousiou, Z.Vogiatzoglou, A.Papayanni, P. G.Georgakopoulou, A.Giannaki, M.Stavridou, F.Vallianou, I.Kammenou, M.Varsamoudi, E.Papadimitriou, V.Giannaki, C.Sileli, M.Stergiouda, Z.Stefanou, G.Kourlaba, G.Triantafyllidou, M.Siotou, E.Karaglani, A.Zotou, E.Chatzika, G.Boukla, A.Apostolou, D.Pitsiou, G.Morfesis, P.Bartzoudis, D.Imprialos, K.Karampatakis, T.Kapravelos, N.Bitzani, M.Theodorakopoulou, M.Serasli, E.Sakellari, I.Fylaktou, A.Tryfon, S.Anagnostopoulos, A.Yannaki, E.
- [45] Immune Responses against the Omicron Variant of SARS-CoV-2 after a Third Dose of COVID-19 Vaccine in Patients Living with Human Immunodeficiency Virus (PLWH): Comparison with Healthcare WorkersVACCINES, 2022, 10 (12)Park, Joung HaChung, HyeminKim, Min-ChulChoi, Seong-HoChung, Jin-Won
- [46] Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D (vol 150, pg 1, 2022)BIOMEDICINE & PHARMACOTHERAPY, 2024, 178Torres, MontserratCasado, GuiomarVigon, LorenaRodriguez-Mora, SaraMateos, ElenaRamos-Martin, FernandoLopez-Wolf, DanielSanz-Moreno, JoseRyan-Murua, PabloTaboada-Martinez, Maria LuisaLopez-Huertas, Maria RosaCervero, MiguelCoiras, Mayte
- [47] SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine respondersFRONTIERS IN PUBLIC HEALTH, 2022, 10Ouyang, JingZaongo, Silvere D.Harypursat, VijayLi, XiaofangRouty, Jean-PierreChen, Yaokai
- [48] Public Health and Economic Impact of Periodic COVID-19 Vaccination with BNT162b2 for Old Adults and High-Risk Patients in an Illustrative Prefecture of Japan: A Budget Impact AnalysisINFECTIOUS DISEASES AND THERAPY, 2024, 13 (10) : 2155 - 2177Nagano, MitsuhiroTanabe, KosukeKamei, KazumasaLim, SooyeolNakamura, HonokaIto, Shuhei
- [49] Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohortsAMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (02) : 245 - 253Nieto, YagoYang, ZixiValdez, Benigno C.Kundu, SuprateekBashir, QaiserRamdial, JeremySrour, SamerQazilbash, Muzaffar
- [50] Rapid and Laboratory SARS-CoV-2 Antibody Testing in High-Risk Hospital Associated Cohorts of Unknown COVID-19 Exposure, a Validation and Epidemiological Study After the First Wave of the PandemicFRONTIERS IN MEDICINE, 2021, 8O'Kelly, BrendanMcLaughlin, RonanO'Doherty, RoseannCarroll, HaileyMurray, RoisinDilworth, RachelCorkery, LauraCotter, Aoife G.McGinty, TaraMuldoon, Eavan G.Cullen, WalterAvramovic, GordanaSheehan, GerardSadlier, DeniseHiggins, MichaelaO'Gorman, PeterDoran, PeterInzitari, RosannaHolden, SineadO'Meara, YvonneEnnis, SeanLambert, John S.